• About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: EPILEPSY

Phase III trials in neurology – 2018 in review

January 24, 2019  

Record number of FDA drug approvals in 2018

January 9, 2019  

Marijuana in neurology – POTential benefit?

March 23, 2018  

Seizure count an inaccurate endpoint in epilepsy trials

August 31, 2017  

AAN 2017 DAILY REPORT

April 27, 2017  

Teratogenic potential of antiepileptic drugs: need for research, patient education

May 25, 2016  

Managing epilepsy: are patients satisfied?

July 23, 2014  

Predictive factors for intractable pediatric epilepsy

June 5, 2013  

Levetiracetam in newly-diagnosed epilepsy: KOMET trial results

February 27, 2013  

AMPA blockade in epilepsy: update on perampanel trials

January 11, 2012  
1
2
3

Browse by Topic

MS (268)
AD (81)
PD (77)
PREVIOUS CONGRESSES (37)
DEPRESSION (36)
MIGRAINE (26)
SCHIZOPHRENIA (25)
STROKE (22)
EPILEPSY (21)
COVID-19 (16)
ECTRIMS 2015 (13)
AAN 2015 (11)
ECTRIMS 2014 (10)
DEMENTIA (10)
ECTRIMS 2018 (10)
ECTRIMS 2019 (10)
ECTRIMS 2013 (9)
AAN 2014 (9)
MS SEQUENCING (9)
AAN 2013 (9)
PSYCHIATRY (8)
AAN 2019 (7)
ACTRIMS-ECTRIMS 2020 (7)
ECTRIMS 2017 (7)
ECTRIMS 2016 (6)
CHARCOT 2013 (6)
CCSVI (5)
BIPOLAR (5)
ANXIETY (5)
AAN 2017 (4)
EAN 2015 (4)
BPD (4)
NeuroSound (4)
AAN 2018 (3)
PAIN (3)
ENS 2013 (3)
AAN 2020 (3)
APA 2014 (2)
EAN 2020 (2)
SPECIAL REPORT (2)
SLEEP (2)
NEW DRUGS (2)
AAN 2016 (2)
ADDICTION (1)
EAN 2019 (1)
LUMBAR PUNCTURE (1)
CONCUSSION (1)
CIDP (1)
Dravet syndrome (1)
hATTR (1)
ALS (1)
SEIZURE (1)
INSOMNIA (1)
WEST NILE (1)
LGS (1)
APA 2016 (1)
EAN 2016 (1)
GUIDELINES (1)
TSC (1)
ECTRIMS 2020 (0)
View all Topics

Popular Posts

  • Multiple sclerosis 2021 – a look ahead posted on January 13, 2021
  • Progression independent of relapses (PIRA) in MS posted on November 21, 2019
  • Ozanimod vs. fingolimod: is there a difference? posted on November 13, 2020
Copyright 2021 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions